Magnetic Resonance Imaging Markers of Brain Health Improve Assessment of Functional Outcome After Acute Ischemic Stroke: A Quantitative Comparison Study

Erik Lindgren[1,2, 3]; Luca Angeleri[1]; Martin Bretzner[4]; Anna K. Bonkhoff[1]; Christina Jern[5,6]; Arne G Lindgren[7]; Jane Maguire[8]; Robert W. Regenhardt[1]; Natalia S. Rost[1]; Markus D. Schirmer[1] and the MRI-GENIE and GISCOME Investigators

1. J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
2. Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg
3. Department of Neurology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden
4. Lille University, Inserm, CHU Lille, U1172—LilNCog—Lille Neuroscience & Cognition, France
5. Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
6. Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden
7. Department of Neurology, Skåne University Hospital; Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden
8. University of Technology Sydney, Sydney, Australia

Corresponding Author:
Erik Lindgren, MD, PhD
JPK Stroke Research Center, Massachusetts General Hospital,
175 Cambridge St,
02114, Boston, MA, US
elindgrenbogdanoff@mgh.harvard.edu, erik.lindgren@neuro.gu.se
phone: +46 702735465, +1 857 298 9297

Supplemental data: eMethods, eResults, eTable 1, eTable 2, eFigure 1

Key words: brain health; stroke; acute ischemic stroke; outcome; imaging;

Abstract
Objectives:
To compare quantitative MRI markers of brain health in their ability to predict functional outcome after acute ischemic stroke (AIS).

Methods:
We included AIS survivors from the international MRI-GENIE study (multicenter; 2003-2011) with acute T2-FLAIR imaging. Automated pipelines estimated white matter hyperintensity volume (WMHv), brain volume, and intracranial volume (ICV). Assessed brain health markers included: brain parenchymal fraction (brain volume relative to ICV); radiomics derived brain age; brain reserve (normal appearing brain volume relative to ICV), and effective Reserve (eR, latent variable based on age, WMH load and brain volume). We added the markers to a clinical reference model, comparing model performances between separate multivariable regression models in their prediction of unfavorable outcome (90-day modified Rankin Scale score 3-5), using Bayesian Information Criterion (BIC).

Results:
We analyzed 2,223 patients (median age 67 years, 45% female, 24% unfavorable outcome). All models using brain health markers outperformed the clinical reference model (ΔBIC > 10). The eR model showed the lowest BIC value (BIC=2171.8), providing strong statistical evidence to outperform the brain age model (BIC=2179.5, ΔBIC > 6), and very strong (ΔBIC > 10) statistical evidence to outperform all other models.

Discussion
Quantitative MRI markers of brain health, especially eR, enhance personalized outcome prognostication after AIS.

Introduction

Brain health facilitates resilience to withstand detrimental effects of brain disease, and has been widely recognized as an essential research goal by international organizations, including the American Academy of Neurology.[1] While stroke is the leading global contributor to long-term disability, the importance of brain health for functional outcome after acute ischemic stroke (AIS) remains relatively underexplored.[2] Time sensitive acute patient management limits comprehensive cognitive assessment, but automated assessment of routinely acquired magnetic resonance imaging (MRI) markers presents opportunities for a standardized and prompt quantification of structural brain health, with the potential to inform personalized clinical decision making.

We aimed to compare four quantitative MRI markers of brain health that can be assessed in the acute stroke setting using automated deep learning enabled pipelines. In a large multicenter clinical cohort, we compared these markers to each other and to a reference model with only clinical variables in terms of the ability to predict functional outcome after AIS.

Methods

This report adheres to international guidelines for reporting observational studies.[3] Additional methodological description is presented in the Supplement.

Standard protocol approval, registration and patient consent

Each participating center received permission from local authorities and ethics committees to collect observational data and obtained written informed consent from participants or their surrogates at time of enrollment, when required under applicable laws.

Participants

We analyzed data from the MRI-GENetics Interface Exploration (MRI-GENIE) study, an international AIS cohort (multicenter, 2003-2011). Details of MRI-GENIE have been described previously.[4] Patients with available acute MRI including T2-Fluid-attenuated inversion recovery (FLAIR) sequences were eligible.

Phenotypical data

Data on clinical characteristics (stroke severity according to National Institutes of Health Stroke Scale [NIHSS]), demographics and medical history were collected at hospital admission. Functional outcome was assessed at approximately 90 days post-stroke, using the modified Rankin Scale (mRS). To investigate brain health and functional independence, we defined unfavorable outcome as mRS score 3-5.[5]

Neuroimaging

Neuroimaging was obtained during admission as part of routine care using clinical AIS protocols. We automatically assessed white matter hyperintensity volume (WMH), intracranial volume (ICV) and brain volume (combined gray matter and white matter parenchymal volumes) based on FLAIR, utilizing pipelines specifically developed for MRI sequences acquired in the acute clinical setting of AIS patients.[6,7] Results were

manually reviewed, and failed segmentations, e.g. due to image artifacts, were excluded. We normalized WMH by individual brain volumes, creating WMH load for each patient.

We assessed four neuroimaging markers of brain health described in the literature: 1) brain parenchymal fraction (BPF)[8] – brain volume relative to ICV; 2) radiomics derived brain age (BA)[9] – based on an ElasticNet linear regression model; 3) brain reserve (BR)[10] – normal appearing brain volume (brain volume minus WMH volume) relative to ICV; and 4) effective Reserve (eR)[11] – a latent variable estimated based on the observed variables age, WMH load and brain volume. Pathway coefficients used to estimate eR in the study cohort were derived from an independent cohort.[11]

Statistical analysis

We report continuous data as medians with interquartile ranges (IQR) and dichotomous data as proportions of investigated patients. We excluded patients with incomplete data (see eFigure 1).

We defined a clinical reference logistic regression model to predict unfavorable outcome (mRS score 3-5 at 90 days) including the clinical variables age, sex, diabetes mellitus type 2, hypertension and stroke severity (NIHSS). To this reference model, investigated MRI brain health markers were added creating four brain health models. We compared the predictive performances between these four brain health models and the reference model in terms of goodness-of-fit using Bayesian Information Criterion (BIC).[12] We calculated the area under the precision-recall curve (PR-AUC) with 95% CI using 10-fold cross-validation with 100 iterations, comparing mean values of calculated integrals to the reference model using Mann Whitney U tests. The PR-AUC resembles the traditional receiver operating characteristic AUC, while being more accurate in unbalanced datasets.[13]

All analyses were performed using R (version 4.4.1; R Foundation for Statistical Computing) with significance level set to $p<0.05$.

Data Availability

Data, methods and materials will be made available for the purpose of reproducing the results, subject to approval by the local Institutional Review Boards.

Results

We analyzed 2,375 patients (median age 67 years, 45% female), of which 152 (6.4%) were excluded due to incomplete phenotypical data or insufficient imaging quality (see eFigure 1). Baseline characteristics stratified by outcome categories appear in Table 1.

Investigated models are presented with their corresponding BICs and PR-AUC values in Table 2 and graphically with adjusted odds ratios (aORs) and 95% CI in Figure 1. Comparison using BIC provided very strong statistical evidence ($\Delta BIC > 10$)[12] for all four models including a brain health marker to outperform the reference model.

The model utilizing eR showed the lowest BIC value (BIC=2171.8), providing strong (ΔBIC > 6), and very strong (ΔBIC > 10) statistical evidence to outperform the BA (BIC=2179.5) and all other models respectively (see Table 2).[12] Compared to the reference model (0.728, 95%CI 0.648-0.792), the PR-AUC values were significantly higher in the eR (0.742, 95%CI 0.666-0.820, p=0.007) and BA (0.738, 95%CI 0.657-0.800, p=0.033), but not BPF or BR models.

Discussion

In this international observational multicenter study, we demonstrate that the addition of neuroimaging brain health markers enhance modeling of functional outcome after AIS. The model utilizing effective Reserve (eR) outperformed all other investigated models, highlighting eR as a promising marker to quantify brain health in clinical settings.

Our findings are in line with previous studies showing the importance of incorporating brain health markers to predict outcomes after neurological diseases.[8-11,14] Mostly smaller cohorts have explored use of brain health markers specifically in stroke, but often relying on high quality imaging data and manual assessment.[8,14,15] Here, we further demonstrate use of automatized pipelines that enable translation into the routine acute stroke setting, bringing the holistic concept of *brain health in stroke* closer to clinical implementation.

Both eR and radiomics derived BA outperformed the other models, with lower BICs and higher PR-AUCs compared to the clinical reference model. These results were consistent regarding BICs but not PR-AUCs when comparing to a clinical reference and brain health models adjusting more comprehensively also for WMH load and brain volume (eTable 1). A possible explanation is that BPF and BR have not been specifically developed to quantify brain health in stroke populations and BR not taking present pathology into account. The latent variable approach used to estimate eR and the radiomics approach to calculate BA may capture more nuanced signals of brain health, as compared to markers of brain volume, WMH and ICV, combined or alone.

Strengths of this study include the large international multicenter setting with standardized automated central adjudication of imaging to quantify brain health. Several limitations warrant comment. First, study participants were enrolled between 2003-2011 and detailed treatment data were not available. The cohort may hence not be fully representative of current stroke care, involving more inclusive and advanced reperfusion therapies. Second, investigated brain health markers are dependent on MRI which is not broadly available in acute stroke care worldwide. Third, only structural measures of brain health were considered. Cognitive aspects of brain health and a wider variety of outcomes, e.g. those obtained via patient reported outcome measures (PROMs), remain to be investigated. Next steps should further investigate how AIS or modifiable risk factors influence brain health and whether brain health modifies the outcome after stroke.

In conclusion, our results emphasize the importance of incorporating MRI measures of brain health for personalized outcome prognostication after AIS and suggest eR as a viable marker for future studies investigating brain health and stroke.

Study Funding
Research reported in this publication was supported by the Swedish Research Council (2023-06531), the Swedish Heart Lung Foundation (no. 20230904, 2024135125), The Swedish Brain Foundation, The Swedish Government (under the “Avtal om Läkarutbildning och Medicinsk Forskning, ALF”), Lund University, Region Skåne, The FGS Fang Foundation, The Fremasons Lodge of Instruction Eos in Lund, The Swedish Stroke Association, AI Cures Grant Award, and the National Institute on Aging (NIA R21AG083559).

Disclosure
NSR is supported by NINDS U19NS115388 and the MGB AI Cures Grant Award. AGL is national leader for Sweden for one ongoing stroke trial, local PI for the StrokeCLOSE study, Co-chairs the Global Alliance for International Stroke Genetics Consortium of Acute and Long-term Outcome studies, is Co-PI for The Genetics of Ischaemic Stroke Functional Outcome (GISCOME), and reports personal fees from Arega, Bayer, Astra Zeneca, BMS Pfizer, and Novo Nordisk. RWR serves on a DSMB for a trial sponsored by Rapid Medical, serves as site PI for studies sponsored by MicroVention and Penumbra, and receives research grant support from NIH (NINDS R25NS065743), Society of Vascular and Interventional Neurology, and Heitman Stroke Foundation. MDS is supported by AI Cures Grant Award, Heitman Stroke Foundation, and NIA R21AG083559.

Acknowledgements
The authors thank participating patients and their families and the MRI-GENIE and GISCOME investigators.

Figure 1. Comparison of Models to Predict Functional Outcome (mRS 3-5) at 90 days After Acute Ischemic Stroke

Model	BIC	PR-AUC (95% CI)	p-value
Brain Age	2180	0.738 (0.657-0.800)	0.033
Brain Parenchymal Fraction	2206	0.733 (0.655-0.805)	0.347
Brain Reserve	2201	0.735 (0.658-0.807)	0.199
effective Reserve	2172	0.742 (0.666-0.820)	0.007
Ref	2216	0.728 (0.648-0.792)	Ref



Abbreviations: BIC - Bayesian Information Criterion; PR-AUC – Precision Recall Area Under Curve; Ref – Reference; CI – Confidence Interval; BA – radiomics derived Brain Age; BPF – Brain Parenchymal Fraction; BR – Brain Reserve; eR – effective Reserve; NIHSS – National Institutes of Health Stroke Scale; mRS – modified Rankin Scale; DM – Diabetes Mellitus Type 2; HTN – Hypertension.

Each model and its included variables' adjusted odds ratio appear as a colored dot and corresponding 95% confidence interval line. Lower BIC indicate better model performance. In model selection analysis, evidence levels for statistical differences are considered Weak, Positive, Strong or Very strong for differences in BIC (ΔBIC) larger than 0, 2, 6 and 10 respectively. PR-AUC values for each model including a quantitative MRI marker of brain health are compared to a reference model with only clinical variables using Mann Whitney U test.

Table 1. Characteristics of 2,223 Patients with Acute Ischemic Stroke

Variable	All, n=2,223	mRS 0-2, n=1,683 (76%)	mRS 3-5, n=540 (24%)	p-value
Demographics				
Age, years (median, [IQR])	67.0 (56.0-76.4)	65.2 (54.8-74.4)	72.6 (62.9-80.1)	<0.001
Sex (F; [%])	1002 (45.1)	707 (42.0)	295 (54.6)	<0.001
Cardiovascular Risk Factors				
Diabetes mellitus type 2 (%)	219 (9.9)	154 (9.2)	65 (12.0)	0.061
Hypertension (%)	1570 (71)	1145 (68.0)	425 (78.7)	<0.001
Presentation				
NIHSS (median, [IQR])	3 (1-6)	2.00 (1.00-5.00)	5.00 (2.00-9.25)	<0.001
Imaging Characteristics				
Brain volume, cc (median, [IQR])	1250 (1150-1360)	1270 (1170-1380)	1190 (1080-1310)	<0.001
Intracranial volume, cc (median, [IQR])	1610 (1500-1710)	1620 (1510-1730)	1570 (1460-1680)	<0.001
White matter hyperintensity volume, cc (median, [IQR])	3.85 (1.20-9.82)	3.30 (1.05-8.63)	6.05 (2.37-13.7)	<0.001
Brain Health Markers				
Brain Parenchymal Fraction (%, median, [IQR])	78.6 (75.1-81.7)	79.0 (75.9-81.9)	76.9 (72.9-80.4)	<0.001
Brain Age (median, [IQR])	65.7 (55.9-73.6)	63.7 (54.5-72.0)	71.1 (62.6-76.5)	<0.001
Brain Reserve (%, median, [IQR])	78.1 (74.4-81.2)	78.6 (75.4-81.5)	76.2 (72.2-80.0)	<0.001
Effective Reserve (A.U., median, [IQR])	-0.347 (-0.839-0.131)	-0.257 (-0.729-0.241)	-0.683 (-1.14--0.248)	<0.001

Abbreviations: SD – standard deviation; IQR – Interquartile range; NIHSS – National Institutes of Health Stroke Scale; cc – cubic centimeters; mRS – modified Rankin Scale; A.U. – Arbitrary Units

Table 2. Comparison of Investigated Models Including a Quantitative MRI Marker of Brain Health to Predict Functional Outcome at 90 Days After Acute Ischemic Stroke

Model	Included variables	aOR	95% CI	P-value	BIC	PR-AUC (95% CI)
Reference	Age	1.03	1.03 - 1.04	<0.001	2216.3	0.728 (0.648 - 0.792) p-value: N/A
	Female	1.52	1.23 - 1.87	<0.001		
	Diabetes Type 2	1.35	0.97 - 1.87	0.072		
	Hypertension	1.36	1.06 - 1.76	0.017		
	NIHSS	1.14	1.12 - 1.17	<0.001		
Brain Parenchymal Fraction (BPF)	BPF, %	0.95	0.93 - 0.97	<0.001	2206.1	0.733 (0.655 - 0.805) p-value: 0.347
	Age	1.03	1.02 - 1.03	<0.001		
	Female	1.54	1.24 - 1.90	<0.001		
	Diabetes Type 2	1.41	1.01 - 1.95	0.042		
	Hypertension	1.31	1.02 - 1.70	0.036		
	NIHSS	1.15	1.12 - 1.17	<0.001		
Brain Age (BA)	BA	1.05	1.04 - 1.06	<0.001	2179.5	0.738 (0.657 - 0.800) p-value: 0.033
	Female	1.64	1.33 - 2.03	<0.001		
	Diabetes Type 2	1.29	0.92 - 1.79	0.133		
	Hypertension	1.30	1.01 - 1.68	0.046		
	NIHSS	1.14	1.12 - 1.17	<0.001		
Brain Reserve (BR)	BR, %	0.95	0.92 - 0.97	<0.001	2200.9	0.735 (0.658- 0.807) p-value: 0.199
	Age	1.02	1.01 - 1.03	<0.001		
	Female	1.54	1.25 - 1.90	<0.001		
	Diabetes Type 2	1.39	0.99 - 1.92	0.051		
	Hypertension	1.30	1.01 - 1.69	0.044		
	NIHSS	1.15	1.12 - 1.17	<0.001		
effective Reserve (eR)	eR	0.39	0.32 - 0.47	<0.001	2171.8	0.742 (0.666 - 0.820) p-value: 0.007
	Female	1.08	0.86 - 1.35	0.519		
	Diabetes Type 2	1.26	0.90 - 1.75	0.171		
	Hypertension	1.23	0.95 - 1.59	0.122		
	NIHSS	1.15	1.12 - 1.17	<0.001		

Abbreviations: aOR – adjusted Odds Ratio; BIC – Bayesian Information Criterion; CI – Confidence Interval; PR-AUC – Area Under the Precision Recall Curve; NIHSS – National Institutes of Health Stroke Scale; WMH – white matter hyperintensity; BPF – Brain Parenchymal Fraction; BA – Radiomics derived Brain Age; BR – Brain Reserve; eR – effective Reserve.

References

1. Rost NS, Salinas J, Jordan JT, et al. The Brain Health Imperative in the 21st Century-A Call to Action: The AAN Brain Health Platform and Position Statement. *Neurology*. Sep 26 2023;101(13):570-579. doi:10.1212/wnl.0000000000207739
2. Ferrari AJ, Santomauro DF, Aali A, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet*. 2024;403(10440):2133-2161. doi:10.1016/S0140-6736(24)00757-8
3. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*. Oct 20 2007;370(9596):1453-7. doi:10.1016/s0140-6736(07)61602-x
4. Giese AK, Schirmer MD, Donahue KL, et al. Design and rationale for examining neuroimaging genetics in ischemic stroke: The MRI-GENIE study. *Neurol Genet*. Oct 2017;3(5):e180. doi:10.1212/nxg.0000000000000180
5. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. *J Neurol Neurosurg Psychiatry*. Dec 1991;54(12):1044-54. doi:10.1136/jnnp.54.12.1044
6. Alhadid K, Regenhardt RW, Rost NS, Schirmer MD. Brain volume is a better biomarker of outcomes in ischemic stroke compared to brain atrophy. Original Research. *Frontiers in Stroke*. 2024-October-29 2024;3doi:10.3389/fstro.2024.1468772
7. Schirmer MD, Dalca AV, Sridharan R, et al. White matter hyperintensity quantification in large-scale clinical acute ischemic stroke cohorts - The MRI-GENIE study. *Neuroimage Clin*. 2019;23:101884. doi:10.1016/j.nicl.2019.101884
8. Bu N, Khlif MS, Lemmens R, et al. Imaging Markers of Brain Frailty and Outcome in Patients With Acute Ischemic Stroke. *Stroke*. Mar 2021;52(3):1004-1011. doi:10.1161/strokeaha.120.029841
9. Bretzner M, Bonkhoff AK, Schirmer MD, et al. Radiomics-Derived Brain Age Predicts Functional Outcome After Acute Ischemic Stroke. *Neurology*. Feb 21 2023;100(8):e822-e833. doi:10.1212/wnl.0000000000201596
10. Zijlmans JL, Lamballais S, Lahousse L, et al. The interaction of cognitive and brain reserve with frailty in the association with mortality: an observational cohort study. *The Lancet Healthy Longevity*. 2021;2(4):e194-e201. doi:10.1016/S2666-7568(21)00028-3
11. Schirmer MD, Alhadid K, Regenhardt RW, Rost NS. Quantifying Brain Health in Acute Ischemic Stroke Through Effective Reserve. *Neurology*. Mar 11 2025;104(5):e210180. doi:10.1212/wnl.0000000000210180
12. Raftery AE. Bayesian model selection in social research. *Sociological methodology*. 1995:111-163.
13. Boyd K, Eng KH, Page CD. Area under the Precision-Recall Curve: Point Estimates and Confidence Intervals. Springer Berlin Heidelberg; 2013:451-466.
14. Appleton JP, Woodhouse LJ, Adami A, et al. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke. *Neurology*. Feb 4 2020;94(5):e439-e452. doi:10.1212/wnl.0000000000008881

15. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial. *Lancet Neurol*. May 2015;14(5):485-96. doi:10.1016/s1474-4422(15)00012-5

Magnetic Resonance Imaging Markers of Brain Health Improve Assessment of Functional Outcome After Acute Ischemic Stroke: a Quantitative Comparison Study

Supplement

eMethods

We used the STROBE cross sectional checklist when writing our report.[1]

Participants and Phenotypical Data

Participants aged 90 years and older were aggregated into a single age category in accordance with the Health Insurance Portability and Accountability Act (HIPAA).

The modified Rankin Scale (mRS) used to assess functional outcome at 90 days is a 7-grade ordinal scale ranging from 0 representing no symptoms, to 6 representing death.[2]

Number of included patients from each center appear in eTable 2.

Neuroimaging

Neuroimaging was obtained at onset as part of routine care using clinical AIS protocols with most scans being obtained within 48 hours of hospital admission (median: 2 days, interquartile range 1–4 days). All images were either obtained on 1T, 1.5T or 3T scanners (General Electric Medical Systems, Philips Medical Systems, Siemens, Toshiba, Marconi Medical Systems, Picker International Inc.). All volumes (WMH volume, brain volume) were calculated multiplying number of voxels by voxel size.

Brain Health Models and Comparisons

Models were controlled for multicollinearity using variance inflation factor (VIF). We assessed normal distributions using Shapiro-Wilk test and applied log transformation when applicable. WMH load was log transformed for normality.

We evaluated the predictive performance of brain health markers in separate multivariate logistic regression models with poor outcome (mRS score 3-5 at 90 days) as the dependent variable. All models were adjusted for sex, diabetes mellitus type 2, hypertension and stroke severity (NIHSS). Adjustment for age was conducted if not used to determine the respective brain health marker (see Table 2).

We compared the predictive performances between brain health models and to the reference model in terms of BIC values and PR-AUC values. A lower BIC value represents relatively superior model performance, and the methodology includes penalizing to more complex models to minimize risk for overfitting. In model selection analysis, evidence levels for statistical differences are considered weak, positive, strong or very strong for differences in BIC (ΔBIC) values larger than 0, 2, 6 and 10 respectively.[3] The PR-AUC values were calculated using 10-fold cross validation with 100 iterations. In each iteration, test cohorts were formed by randomly selecting 100 positive and negative outcomes defined as mRS 3-5 and 0-2 respectively. The

remaining dataset (data - test cohort), formed the training cohort used to train models. Mean PR-AUC values and corresponding 95% CI were calculated in the test cohorts from stored predicted probabilities PR-AUC integrals. P-values were calculated using Mann Whitney u tests with significance level set to $p<0.05$.

In a subanalysis, we conducted the same analyses in more complex models with more comprehensive adjustments also for WMH load and brain volume if not used to determine the respective brain health marker (see eTable1).

eResults

Results from the subanalysis are presented with the models' corresponding BICs and PR-AUC values in eTable 1. Model comparison using BIC provided very strong statistical evidence for eR (BIC=2171.8, ΔBIC > 10) to outperform BPF (BIC=2189.9), BR (BIC=2200.9) and the reference models (BIC=2181.9) and positive statistical evidence to outperform the BA model (ΔBIC > 2, BIC=2175.7). The model utilizing BA outperformed the reference model (ΔBIC > 6) and the BPF and BR models (ΔBIC > 10). In the subanalysis, we observed no difference in PR-AUC values as compared to the reference model.

eFigure 1. Flow Chart of Included Patients



eTable 1. Comparison of Extended Models Including Quantitative MRI Measures of Brain Health to Predict Functional Outcome at 90 Days After Stroke

Model	Included variables	aOR	95% CI	P-value	BIC	PR AUC (95% CI)
Reference	Age	1.01	1.003 - 1.02	0.014	2181.9	0.743 (0.665 - 0.819) p-value: ref
	Female	1.11	0.87 - 1.42	0.388		
	Diabetes Type 2	1.17	0.83 - 1.63	0.361		
	Hypertension	1.22	0.94 - 1.58	0.139		
	NIHSS	1.15	1.13 - 1.17	<0.001		
	WMH load	1.24	1.14 - 1.35	<0.001		
	Brain Volume	0.997	0.997 - 0.998	<0.001		
Brain Parenchymal Fraction (BPF)	BPF, %	0.95	0.92 - 0.97	<0.001	2189.9	0.742 (0.668 - 0.812) p-value: 0.706
	Age	1.01	1.00 - 1.02	0.016		
	Female	1.58	1.28 - 1.96	<0.001		
	Diabetes Type 2	1.21	0.86 - 1.69	0.262		
	Hypertension	1.24	0.96 - 1.61	0.100		
	NIHSS	1.15	1.12 - 1.17	<0.001		
	WMH load	1.23	1.13 - 1.34	<0.001		
Brain Age (BA)	BA	1.04	1.03 - 1.06	<0.001	2175.7	0.741 (0.665 - 0.806) p-value: 0.886
	Female	1.65	1.34 - 2.04	<0.001		
	Diabetes Type 2	1.17	0.83 - 1.63	0.369		
	Hypertension	1.25	0.97 - 1.63	0.085		
	NIHSS	1.15	1.12 - 1.17	<0.001		
	WMH load	1.15	1.06 - 1.26	0.001		
Brain Reserve (BR)	BR, %	0.95	0.92 - 0.97	<0.001	2200.9	0.735 (0.658 - 0.807) p-value: 0.106
	Age	1.02	1.01 - 1.03	<0.001		
	Female	1.54	1.25 - 1.90	<0.001		
	Diabetes Type 2	1.39	0.99 - 1.92	0.051		
	Hypertension	1.30	1.01 - 1.69	0.044		
	NIHSS	1.15	1.12 - 1.17	<0.001		
effective Reserve (eR)	eR	0.39	0.32 - 0.47	<0.001	2171.8	0.742 (0.666 - 0.820) p-value: 0.915
	Female	1.08	0.86 - 1.35	0.519		
	Diabetes Type 2	1.26	0.90 - 1.75	0.171		
	Hypertension	1.23	0.95 - 1.59	0.122		
	NIHSS	1.15	1.12 - 1.17	<0.001		

Abbreviations: aOR – adjusted Odds Ratio; BIC – Bayesian Information Criterion; CI – Confidence Interval; PR-AUC – Area Under the Precision Recall Curve; NIHSS – National Institutes of Health Stroke Scale; WMH – white matter hyperintensity; BPF – Brain Parenchymal Fraction; BA – Radiomics derived Brain Age; BR – Brain Reserve; eR – effective Reserve.

eTable 2. Participating Centers and Included Patients

Country	Center	Included Patients
MRI-GENIE		***N=2,223***
Belgium	University Hospitals, Leuven	369 (17%)
Finland	Helsinki University Hospital, Helsinki	223 (10%)
Sweden	Skåne University Hospital Lund, Lund (Lund Stroke Register)	75 (3%)
Sweden	Sahlgrenska University Hospital, Gothenburg (SAHLSIS)	79 (4%)
Spain	IMIM-Hospital del Mar, Barcelona, (BASICMAR)	87 (4%)
USA	Geisinger, PA	1166 (52%)
USA	University of Cincinnati, OH (GCNKSS)	94 (4%)
USA	Massachusetts General Hospital, MA	130 (6%)

MRI-GENIE - MRI-GENetics Interface Exploration study

eReferences

1. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*. Oct 20 2007;370(9596):1453-7. doi:10.1016/s0140-6736(07)61602-x
2. Banks JL, Marotta CA. Outcomes Validity and Reliability of the Modified Rankin Scale: Implications for Stroke Clinical Trials. *Stroke*. 2007/03/01 2007;38(3):1091-1096. doi:10.1161/01.STR.0000258355.23810.c6
3. Raftery AE. Bayesian model selection in social research. *Sociological methodology*. 1995:111-163.